From gut to lung: Microbiota-derived metabolites reshaping the tumor immune microenvironment 

Prabesh Baniya et al.

EXCLI J. 2026 Aug 20;25:1383-1387. doi: 10.17179/excli2026-9646. eCollection 2026.

Published on October 7, 2026

Abstract

ABSTRACT

Lung cancer remains the leading cause of cancer-related mortality worldwide, and non- small cell lung cancer (NSCLC), which comprises the vast majority of lung cancer cases, has benefited from major therapeutic progress through targeted therapies and immune checkpoint inhibitors (ICIs). Although ICIs targeting the programmed cell death protein-1 (PD-1)/pro- grammed death-ligand 1 (PD-L1) axis have revolutionized the management of advanced NSCLC, only a subset of patients achieves durable clinical benefit, underscoring the urgent need to identify novel biomarkers and therapeutic strategies that can improve treatment effi- cacy. Emerging evidence indicates that the gut microbiota shapes the pulmonary tumor micro- environment, including in NSCLC (Jin et al., 2019).

PMID:42840252 | PMC:PMC13639179 | DOI:10.17179/excli2026-9646

 Read More

← Back to Publications
Mikkola Lea et al.Biochem Biophys Rep. 2026 Nov 9;48:102875. doi: 10.1016/j.bbrep.2026.102875. eCollection 2026 Dec.
Gautier Follain et al.Bio Protoc. 2026 Nov 5;16(21):e5861. doi: 10.21769/BioProtoc.5861. eCollection 2026 Nov 5.
Francesca Bottanelli et al.J Cell Sci. 2026 Nov 1;139(21):jcs265433. doi: 10.1242/jcs.265433. Epub 2026 Nov 12.
Aliaa E Ali et al.Hum Mutat. 2026 Nov 8;2026:8234670. doi: 10.1155/humu/8234670. eCollection 2026.
Marie Christine Goess et al.J Crohns Colitis. 2026 Nov 7;20(11):jjag182. doi: 10.1093/ecco-jcc/jjag182.